Randomized Controlled Trial of Huanglian Jiedu Decoction in Improving Cognitive Function and Neuroinflammation in Patients with Vascular Dementia
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i1.3677
Abstract
Background and Objective: Huanglian Jiedu Decoction (HLJD) is commonly used for patients with vascular dementia (VaD) in China. Objective: To evaluate the clinical efficacy of HLJD through a randomized controlled trial (RCT). Methods: The control group received Donepezil Hydrochloride tablets, while the experimental group received Donepezil Hydrochloride tablets combined with HLJD. Both groups were treated for 8 weeks. The clinical efficacy and incidence of adverse reactions were compared between the two groups. The MMSE and MoCA scales were used to assess cognitive function. Inflammatory cytokines IL-6, IL-1β, TNF-α, and hs-CRP were also compared. Results: After treatment, the effective rate in the control group was 28.13%, while the effective rate in the experimental group was 56.67%, significantly higher than that in the control group (P<0.05). After treatment, the MMSE and MoCA scores of both groups increased significantly compared to baseline (P<0.01). The MMSE score in the experimental group was higher than that in the control group (P<0.01), and the MoCA score in the experimental group was also higher than that in the control group (P<0.05). After treatment, the levels of inflammatory cytokines IL-6, IL-1β, TNF-α, and hs-CRP in both groups decreased significantly compared to baseline (P<0.01). The experimental group showed better results in reducing the levels of these inflammatory cytokines than the control group (P<0.01). Additionally, the total clinical efficacy rate in the experimental group was 96.00%, higher than the 82.00% in the control group (P<0.05). Conclusion: HLJD combined with Donepezil can provide symptomatic benefits for patients with mild to moderate VaD.
Keywords
Vascular dementia, Huanglian Jiedu Decoction, Randomized Controlled, TrialInflammatory factors, Cognitive function
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Morgan A E, Mc A M. Vascular dementia: From pathobiology to emerging perspectives[J]. Ageing Res Rev. 2024, 96: 102278.
[2] Chang W E, Chang C H. Vascular Cognitive Impairment and Dementia[J]. Continuum (Minneap Minn). 2022, 28(3): 750-780.
[3] Jiao C, Wei S, Liu T, et al. The Prevalence of Vascular Dementia in China: A Systematic Review and Meta-Analysis from 2009-2019[J]. Iran J Public Health. 2021, 50(1): 11-23.
[4] Roman G C, Tatemichi T K, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop[J]. Neurology. 1993, 43(2): 250-260.
[5] Folstein M F, Folstein S E, Mchugh P R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res. 1975, 12(3): 189-198.
[6] Gottesman R F, Hillis A E. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke[J]. Lancet Neurol. 2010, 9(9): 895-905.
[7] Wang X X, Zhang B, Xia R, et al. Inflammation, apoptosis and autophagy as critical players in vascular dementia[J]. Eur Rev Med Pharmacol Sci. 2020, 24(18): 9601-9614.
[8] Tian Z, Ji X, Liu J. Neuroinflammation in Vascular Cognitive Impairment and Dementia: Current Evidence, Advances, and Prospects[J]. Int J Mol Sci. 2022, 23(11).
[9] Xing S H Z C. Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis.[J]. Evidence-Based Complementray and Alternative Medicine. 2014 (2014): 363985.
[10] Bar K J, Boettger M K, Seidler N, et al. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy[J]. Stroke. 2007, 38(12): 3186-3192.
[11] Kandiah N, Pai M C, Senanarong V, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia[J]. Clin Interv Aging. 2017, 12: 697-707.
[12] Appleton J P, Scutt P, Sprigg N, et al. Hypercholesterolaemia and vascular dementia[J]. Clin Sci (Lond). 2017, 131(14): 1561-1578.
[13] Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia[J]. Cochrane Database Syst Rev. 2019, 2019(11).
[14] Sowndhararajan K, Deepa P, Kim M, et al. Neuroprotective and Cognitive Enhancement Potentials of Baicalin: A Review[J]. Brain Sci. 2018, 8(6).
[15] Wang Z, Yang Y, Liu M, et al. Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review[J]. Curr Vasc Pharmacol. 2020, 18(4): 358-368.
[2] Chang W E, Chang C H. Vascular Cognitive Impairment and Dementia[J]. Continuum (Minneap Minn). 2022, 28(3): 750-780.
[3] Jiao C, Wei S, Liu T, et al. The Prevalence of Vascular Dementia in China: A Systematic Review and Meta-Analysis from 2009-2019[J]. Iran J Public Health. 2021, 50(1): 11-23.
[4] Roman G C, Tatemichi T K, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop[J]. Neurology. 1993, 43(2): 250-260.
[5] Folstein M F, Folstein S E, Mchugh P R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician[J]. J Psychiatr Res. 1975, 12(3): 189-198.
[6] Gottesman R F, Hillis A E. Predictors and assessment of cognitive dysfunction resulting from ischaemic stroke[J]. Lancet Neurol. 2010, 9(9): 895-905.
[7] Wang X X, Zhang B, Xia R, et al. Inflammation, apoptosis and autophagy as critical players in vascular dementia[J]. Eur Rev Med Pharmacol Sci. 2020, 24(18): 9601-9614.
[8] Tian Z, Ji X, Liu J. Neuroinflammation in Vascular Cognitive Impairment and Dementia: Current Evidence, Advances, and Prospects[J]. Int J Mol Sci. 2022, 23(11).
[9] Xing S H Z C. Huperzine A in the Treatment of Alzheimer's Disease and Vascular Dementia: A Meta-Analysis.[J]. Evidence-Based Complementray and Alternative Medicine. 2014 (2014): 363985.
[10] Bar K J, Boettger M K, Seidler N, et al. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy[J]. Stroke. 2007, 38(12): 3186-3192.
[11] Kandiah N, Pai M C, Senanarong V, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia[J]. Clin Interv Aging. 2017, 12: 697-707.
[12] Appleton J P, Scutt P, Sprigg N, et al. Hypercholesterolaemia and vascular dementia[J]. Clin Sci (Lond). 2017, 131(14): 1561-1578.
[13] Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia[J]. Cochrane Database Syst Rev. 2019, 2019(11).
[14] Sowndhararajan K, Deepa P, Kim M, et al. Neuroprotective and Cognitive Enhancement Potentials of Baicalin: A Review[J]. Brain Sci. 2018, 8(6).
[15] Wang Z, Yang Y, Liu M, et al. Rhizoma Coptidis for Alzheimer's Disease and Vascular Dementia: A Literature Review[J]. Curr Vasc Pharmacol. 2020, 18(4): 358-368.
Copyright © 2025 Mingyue Cui, Leilei Wang, Tingting Wang, Zhixing Chen, Youxiang Cui
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
